Viatris 的子公司 Mylan 被美国司法部排除在仿制药价格操纵反垄断调查之外。 Viatris' subsidiary Mylan removed from US DOJ antitrust probe on generic drug price-fixing.
Viatris 的子公司 Mylan 已被排除在美国司法部 (DOJ) 对仿制药行业价格操纵的反垄断调查之外。 Viatris' subsidiary Mylan has been removed from the U.S. Department of Justice's (DOJ) antitrust investigation into price-fixing in the generic drug industry. 美国司法部民事部门表示，他们预计不会针对迈兰仿制药的定价和销售采取进一步行动，但 Viatris 将继续针对相关民事诉讼为自己辩护。 The DOJ's Civil Division stated they do not anticipate further action concerning Mylan's generic drug pricing and sales, but Viatris will continue to defend itself against related civil litigation. 迈兰公司退出调查的原因尚未具体说明。 The reasons for Mylan's removal from the probe were not specified.